Toward a statistically relevant calibration end point for prostate seed implants.
Interstitial brachytherapy for carcinoma of the prostate is achieved through the use of a configuration of radioactive seeds placed in a manner that delivers a customized, reasonably uniform dose to the target volume. Accurate dose delivery depends on both precise seed placement and reliable seed strength in the implanted configuration. This study assumes the independence of the two issues, and quantifies the reduction in the minimum dose to the surface of the gland due only to variability in individual seed strengths. Current AAPM guidelines pertaining to the acceptable limits on seed-to-seed variability are prudent for small configurations of seeds, yet are likely to be overly stringent for applications such as prostate seed implantation. In this study we determine the reduction in the minimum peripheral dose (mPD) caused by the introduction of source strength variability, and provide statistical insight into this effect. It is concluded that the current guidelines limit the reduction in mPD to < or =0.4% relative to the prescription value, for an average configuration, due to the inclusion of strength variability. The maximum observed reduction in mPD would be < or =1.5%. This value is an order of magnitude lower than the recommendations of the AAPM Task Group 40 for the overall accuracy of brachytherapy procedures, which suggests that seed strength variability is of limited concern and that constraints on this factor should perhaps be reevaluated.
Rosenzweig
D P
DP
Department of Radiation Oncology, University of Rochester Medical Center, New York 14642, USA. rosenrosen@usa.net
Schell
M C
MC
Yu
Y
Y
D055592:Biophysical Phenomena; D001703:Biophysics; D001918:Brachytherapy / Q000592:standards / Q000706:statistics & numerical data*; D003198:Computer Simulation; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D010165:Palladium / Q000008:administration & dosage / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011786:Quality Control; D011868:Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use; D011880:Radiotherapy Planning, Computer-Assisted
D007457:Iodine Radioisotopes; D011868:Radioisotopes; D010165:Palladium